23andMe SPAC Presentation Deck

Our Lead CD96 Program Was Identified With ML and Al Applied to Our Proprietary I/O Genetic Signature Large I/O market with over $41B expected in 2021 sales 2021 projected sales of leadin checkpoint inhibitors KEYTRUDA $17.0B OPDIVO YERVOY $7.9B $1.8B CD96 pathway validated with ML and Al applied to our proprietary I/O genetic signature which also identifies marketed I/O drugs Source: Evaluate Pharma historical and forecast estimates. I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes tonsillectomy- 11d- anti tn alpha or dmards- juvenile ttd- igb.dry skin froquancy- iodine treatment ever- hypothyroidism- hyperthyroidism hashimotos grines vitiago- iqb.dandruff frequency celiac HLA all psoriasis rheumatoid arthrite look meds anti inf_alpha- thyroid removed- immunodeficiency squamous cell carcinoma - basal cell carcinoma actinic keratoss- non melanoma skin cancer- any skin cancer- Autoimmune Cancer We discovered the signaling pathway has a similar genetic I/O signature CD96 plays an important role in NK and T cell antitumor activity APC/Tumor cell GSK 608 T cell/NK cell CD96 + CD155 CD226 ITIM TIGIT GSK'608 (anti-CD96) is progressing through a Phase 1 multi-ascending dose trial in patients with advanced solid tumors 23andMe Confidential and Proprietary Information 28

View entire presentation